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Bone histologic response to deferoxamine in aluminum—related bone
disease. We have examined the changes in bone histology in 28 uremic
patients after long—term treatment with the aluminum chelator,
deferoxamine. Marked declines in stainable bone—surface aluminum
were associated with increases in bone formation rate and osteoblastic
osteoid following deferoxamine. The increased bone formation resulted
from increases in bone apposition and length of double—tetracycline
labels, the latter being highly correlated with the increase in
osteoblastic osteoid (r = 0.85). While bone surface aluminum was
highly correlated with bone formation rate (r = .69, p < .001), bone
aluminum content did not correlate with bone formation (r = 0.13) and
was often elevated after treatment despite an improvement in bone
histology. Patients who had undergone prior parathyroidectomy were
less likely to have improved bone histology than those with intact
parathyroid glands. We conclude that aluminum chelation therapy with
deferoxamine is effective in ameliorating the bone histology of patients
with chronic renal failure and bone aluminum accumulation, and that
the change in stainable bone—surface aluminum is a more sensitive
indicator than the change in bone aluminum content in assessing
adequacy of chelation therapy. Patients who need deferoxamine treat-
ment but have undergone a prior parathyroidectomy will probably
require a more intensive treatment schedule than those who have intact
parathyroid glands.
Bone aluminum accumulation in chronic renal failure was
first identified in groups of uremic patients who underwent
dialysis with aluminum contaminated water [1—4]. More re-
cently, aluminum—related bone disease has developed in pa-
tients with chronic renal failure not yet receiving dialysis [5, 6],
in long—term dialysis patients [71 and in diabetic dialysis pa-
tients [8] not exposed to water contaminated with aluminum,
presumably from intestinal absorption of aluminum from
aluminum—containing phosphate binders.
Successful removal of aluminum during dialysis has been
recently demonstrated using the aluminum chelating agent,
deferoxamine [9—12]. While reports have suggested that
deferoxamine may be effective in the treatment of bone alumi-
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num accumulation [13, 14], long—term studies in a large popu-
lation have not been reported. In the present study, we report
the histologic response of bone to long—term aluminum chela-
tion with deferoxamine in uremic patients with increased
surface—aluminum staining of bone.
Methods
Patients
Twenty—eight patients (23 males and 5 females) underwent
iliac crest bone—biopsies (after double tetracycline labeling)
both before and after intravenous therapy with deferoxamine.
Twenty—one patients were symptomatic with bone pain and/or
nontraumatic fractures and seven were asymptomatic for bone
disease at the start of the study. Patients were included for
study if aluminum staining occupied at least 30% or more of the
mineralized bone surface. Seven patients had undergone a prior
parathyroidectomy, and one patient had insulin—dependent
diabetes mellitus.
Maintenance deferoxamine was administered as an intrave-
nous infusion during the last two hours of dialysis, except in one
patient with chronic renal failure not on dialysis who received
weekly deferoxamine subcutaneously by infusion pump. The
individual weekly dosage of deferoxamine ranged from 2 to 6
grams and the duration of treatment ranged from 6 to 18 months
(mean SD, 11.7 2.7 months). In the dialysis patients,
deferoxamine was given either as a single dose or as two doses
divided by at least a three—day interval while dialyzing on a
thrice weekly schedule. Eleven patients dialyzed in the Seattle
area where the aluminum content of the water was consistently
below 15 jig/liter during deferoxamine treatment; all but one of
the remainder dialyzed with water treated by deionization and
reverse osmosis either at home or in regional dialysis centers.
The one patient without water treatment consistently had
dialysate aluminum levels that ranged from 50 to 70 jig/liter
throughout the treatment period. Each patient continued to
receive aluminum-containing phosphate binders throughout the
study period, in doses adjusted to maintain serum phosphorus
levels of 4.5 to 6.0 mg/l00 ml. Baseline serum biochemistries
are given in Table 1.
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Table 1. Baseline serum biochemistries
Patientsa Normal range
Calcium, mg/dl 10.3 0.7 8.5—10.5
Phosphorus, mg/dl 5.7 1.1 2.5—4.5
Alkaline phosphatase, U/liter 193 132 30—115
Aluminum jig/liter 206 130 <10
Values are mean SD.
a N = 27 except for phosphorus and aluminum where N = 23
Bone biopsy
Iliac crest bone—specimens were taken before and after
treatment with deferoxamine, fixed in iced neutral formalin and
processed as previously described [15]. Histomorphometric
analysis of undecalcified, Goldner—stained sections was done
using a computerized digitizer. Preliminary data in 10 of the
patients have been reported previously [14].
Static bone histologic—measurements included osteoid sur-
face (as percent of total surface), osteoblastic osteoid (cuboidal
or "plump" osteoblasts as percent of total surface), total and
mineralized bone area and endosteal fibrosis (as percent of
tissue area), osteoid area (as percent of total bone area), and
osteoid width (jim). Acid phosphatase staining was utilized for
the identification of osteoclasts [16], which were expressed as
the number of osteoclasts per millimeter of total bone surface.
Sections were also stained with aurin—tricarboxylic acid for the
detection of aluminum on the mineralized bone surface and
within cement lines [17]. The Prussian blue stain was applied for
the detection of iron. The amount of aluminum present was
expressed as: stainable bone—surface aluminum (as percent of
total bone surface), stainable aluminum on the cement—line (as
percent of total stainable aluminum), and total stainable
bone—aluminum (surface and cement lines stained, as mm/mm2
tissue area). In 13 patients, two separate bone samples were
available for measurement of total aluminum content using
flameless atomic absorption spectroscopy as previously de-
scribed [18]. Normal bone aluminum content is 2.4 1.2 mg/kg
dry weight.
Dynamic bone parameters were quantitated on unstained
sections. The bone apposition rate (BAR) was determined by
dividing the distance between the two tetracycline labels by the
number of days between tetracycline administration. The bone
formation rate (BFR) was calculated by multiplying the BAR by
the length of bone surface occupied by double tetracycline
labels. Data from bone in biopsies of 19 normal males (age 21 to
69) from the Seattle area were used for comparisons. The BAR
in the normals ranged from 0.51 to 0.78 jim/day and the BFR
ranged from 106 to 602 jim2/mm2/day.
Biopsies were classified histologically, as previously de-
scribed [19], as mild (osteold area < 15%, fibrosis <0.5% and
BFR  106 jim2/mm2/day), osteitis fibrosa (osteoid area < 15%,
fibrosis  0.5% and BFR  106 jim2/mm2/day), osteomalacia
(osteoid area  15%, fibrosis < 0.5% and BFR < 106
jim2/mm2/day), aplastic (osteoid area <15%, fibrosis < 0.5%
and BFR < 106 jim2/mm2/day), or mixed (osteoid area  15%,
fihrncic  0 5tr,).
Serum parathyroid hormone (PTH)
A radioimmunoassay with an antiserum (CH 9) specific to the
mid-region and carboxy-terminal portions of the PTH molecule
[20] was employed for PTH determinations before and after
deferoxamine treatment in 13 patients. The normal limit for this
assay is < 10 jilEq/ml. To assess acute PTH secretion in seven
other patients, antiserum specific for the amino—terminal por-
tion of PTH was used to measure the PTH response during an
acute hypocalcemic challenge [21] before and after therapy with
deferoxamine. This antiserum does not cross—react with biolog-
ically inactive mid-region/carboxy-terminal P1'H fragments
[22]. The normal range is 11 to 24 pg/mI.
Statistics
All results are expressed as the mean SEM. The Wilcoxon
sign—rank test was used for the comparisons of all paired data
with P < 0.05 as the minimum level of significance. Linear
regression analysis was used for the comparisons of bone
histology.
Results
Bone biopsies
Selected parameters of bone histology are displayed in Table
2 for each type of renal bone disease. Before treatment with
deferoxamine, 11 patients had osteomalacia, 12 had aplastic
disease, four had mild disease, and one patient had mixed bone
disease. Stainable bone—surface aluminum was significantly
greater in the patients with osteomalacia than in the aplastic and
mild groups (P < 0.01). Osteoblastic osteoid was less in both
the osteomalacic and aplastic groups when compared to the
group with mild disease (P < 0.01). Osteoclast number was not
statistically different among the groups. Tetracycline labels
failed to separate in eight patients with osteomalacia and in five
patients with aplastic disease. The mean BAR was lower in the
osteomalacic group than in the mild group (P < 0.01) but not
significantly lower than in the aplastic group (P = 0.057). There
was no difference in bone apposition rate between the mild and
aplastic groups.
As shown in Table 3, stainable bone—surface aluminum was
61 3% before and 21 4% after deferoxamine treatment (P <
0.001). Total stainable bone—aluminum also decreased signifi-
cantly following deferoxamine therapy (2.57 0.19 vs. 1.32
0.25 mm/mm2 tissue area; P < 0.001). Concomitantly, stainable
aluminum on the cement—line increased from 11 2% to 39
5% of the total stainable aluminum (P < 0.001). No iron was
detected on the mineralized bone surface. Among the static
bone histologic—parameters, there was a significant increase in
osteoblastic osteoid and osteoclast number and among the
dynamic bone parameters there were increases in BFR and
BAR following deferoxamine treatment. The increase in
double—tetracycline label length from 0.11 0.04 to 0.40 0.09
mm/mm2 (P < 0.001) represents a greater than 250% change.
There was a negative correlation of stainable bone—surface
aluminum with BFR (r =
—0.47, P < 0.001), BAR (r = —0.61,
P < 0.001), and double—tetracycline labeled surfaces (r =
—0.54,
P < 0.001). BFR correlated with osteoblastic osteoid (r = 0.85,
P < 0.001) primarily because of the high correlation between
double—tetracycline label length and osteoblastic osteoid (r =
0.85. P <0.001). Osteoblastic osteoid also correlated with BAR
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Table 2. Surface bone aluminum, osteoid width, osteoblastic osteoid, osteoclast number, and bone apposition rate in
28 dialysis patients before treatment with deferoxamine
Bone
Type of
histology
Bone surface
aluminum
%
Osteoid
width
un
Osteoblastic
osteoid
%
Osteoclast
number
apposition
rate
stun/day
Osteomalacia (N = 11) 75 17 26 7 0.9 Ø9b 0.27 0.27 0.14 0.28
Aplastic (N = 12) 56 12 11 4 0.8 0,5b 0.38 0.21 0.47 0.39
Mild (N = 4) 44 10 12 5 3.0 1.6 0.92 0.83 0.84 0.30c
Mixed (N = 1) 42 29 19.8 1,25 0.71
a P < 0.01 vs. aplastic and mild
b P < 0.01 vs. mild
P < 0.01 vs. osteomalacia
Normal
Before Aftera value&'
Stainable bone—surface
aluminum, % 61 3 21 4 0
Total stainable bone
aluminum, mm/mm2 2.57 0.19 1.32 0.25 0
Stainable cement—line
aluminum, % of total 11 2 39 5 0
Osteoblastic osteoid %
of total surface 2.0 0.7 4.6 1.1 3.4 0.6
Osteoclasts, no. per
mm bone surface 0.47 0.09 0.89 0.14 0.4 0.1
Bone apposition rate
wn/day 0.39 0.08 0.72 0.14 0.63 0.2
Double tetracycline label
length, mm/mm2 0.11 0.04 0.40 0.09 0.41 0.05
Bone formation rate
,wn2/mm2/day 80 27 388 104 311 39
(r = 0.41, P <0.01). As shown in Figure 1, there was a negative
correlation between the log osteoblastic osteoid and stainable
bone—surface aluminum (r = —0.64, P < 0.001).
Table 4 shows the changes in bone aluminum content,
stainable bone—surface aluminum, BFR, osteoblastic osteoid
and serum PTH in 13 dialysis patients before and after
deferoxamine treatment. Bone aluminum content increased in
two patients, showed no change in one patient, and decreased
by a mean of 23 4% in the remaining 10 patients. Only one
patient had more than a 50% decrease in bone aluminum
content following deferoxamine. There was a significant de-
crease in mean bone aluminum—content from 115 14 mg/kg to
94 14 mg/kg (P <0.02). In the same patients, the stainable
bone—surface aluminum decreased in all but one patient, with
an average decline of 70 6%, and 10 showing more than a 50%
decrease. The mean stainable bone—surface aluminum de-
creased significantly (57 4 vs. 21 5%; P < 0.01). Concom-
itantly, BFR and osteoblastic osteoid increased following
deferoxamine (119 54 vs. 530 196 m2/mm2/day; P < 0.01
and 3.0 1.5 vs. 6.9 2.0%; P < 0.01, respectively). The
pretreatment bone aluminum-content did not correlate with
bone formation rate (r = 0.13), but there was a significant
negative correlation between stainable bone—surface aluminum
and bone formation rate (r = —0.69, P <0.01) in these patients.
One patient (number 12 in Table 4) with consistently high levels
of aluminum in the dialysate (50 to 70 pg/liter), failed to show an
increase in BFR and osteoblastic osteoid despite significant
reductions in bone aluminum content and stainable bone—
surface aluminum. There were no correlations of the duration of
deferoxamine treatment with the change in BFR (r = —0.05) or
with the change in stainable bone—surface aluminum (r =
—0.06).
As shown in Figure 2, 16 of the patients (59%) exhibited a
change in the type of renal osteodystrophy after the treatment
of deferoxamine. Of the 11 patients with osteomalacia, two
changed to aplastic disease, three changed to mild disease, two
changed to osteitis fibrosa, and one changed to a transitional
stage of mild histology in which osteoid area was 31% (baseline,
Table 3. Bone histologic changes in 28 uremic patients before and
after treatment with deferoxamine
25
10
.
0
0
0
00
SS
S 0
0.6
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Values are mean SE.
P < 0.005 vs. Before values
b 19 normal patients normal subjects, aged 21 to 59 years, except for
osteoblast number where N = 7
tE
Stainable bone—surface aluminum
% total surface
Fig. 1. Relationship between log osteoblastic osteoid and stainable
bone—surface aluminum. Closed circles indicate values before
deferoxamine treatment and open circles represent post-treatment
values. (r = —0.64; P < 0.001; N = 56)
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Table 4. Bone aluminum content, stainable bone—surface aluminum, bone formation rate, osteoblastic osteoid,
and serum PTH in 13 patients before and after DFO treatment
.Patient
number
BAC
B
SBA
A
BFR 0bl. Ost.
B
PTH
AB A B A B A
ia 177 159 67 48 0 28 0.1 0.2 3 22 90 80 67 37 0 93 0.6 1.6 23 273 52 71 52 61 19 65 0.6 2.7 2 4
4 103 48 51 17 186 520 4.8 15.4 295 209
5 111 103 37 12 392 308 1.1 2.9 57 94
6 152 152 83 17 0 1130 1.1 12.6 41 98
7 47 45 54 25 I 780 3.1 6.6 82 80
8 46 49 48 3 48 348 1.6 7.5 111 195
9 167 129 42 3 589 2624 19.8 25.7 354 681
10 120 98 57 17 0 380 0.3 2.9 40 39
11 94 57 33 4 314 446 2.4 7.9 64 576
12 213 162 86 24 0 0 1.8 1.2 72 41
13 123 74 66 9 0 174 1.2 2.4 112 103
mean SEM 115 14 94 14b 57 4 21 5C 119 554 530 196C 3.0 1.5 6.9 2.0c 97 30 163 61
Abbreviations are: BAC, bone aluminum content (mg/kg); SBA, stainable bone—surface aluminum (% total surface); BFR, bone formation rate
(sm2/mm2/day); ObI. Ost,, osteoblastic osteoid (% total surface); PTH, mid-region assay (normal, < 10 dEq/ml); B, before; A, after. a Patients
who had a prior parathyroidectomy. b P < 0,02 vs. before and C P < 0.01 vs. before.
Fig. 2. Changes in bone histologic classification following deferox-
amine therapy. (*) indicates mild bone histology except that osteoid
area was 31% compared to 41% before deferoxamine treatment (that is,
transitional stage). Closed circles indicate patients who had undergone
prior parathyroidectomy. Open box indicates one patient who did not
have tetracycline labeling on final biopsy to determine bone formation
rate.
41%) after eight months of treatment. Among the 12 patients
with aplastic bone disease, eight changed to mild disease and
three remained aplastic. One patient with aplastic disease
initially could not be categorized on the final biopsy because
tetracycline was not given. However, since there was only a
modest increase in osteoblastic osteoid (from 0.9% to 1.3%),
any increase in BFR from baseline (BFR=0) was probably not
sufficient to change the disorder from the aplastic category. All
of the patients with mild or mixed bone histology remained with
that diagnosis on the follow—up biopsy. Among the patients
with osteomalacia and aplastic disease who did not change their
histologic classification (6 patients), five had undergone a pre-
vious parathyroidectomy.
Serum PTH
As shown in Table 4, the mean serum PTH did not change
significantly following deferoxamine treatment (before, 97 30
pg/mi; after, 163 61 pg/mI, P = 0.48) in the 13 patients in
which these measurements were made. Six of these patients
had osteomalacia (patients 1, 3, 6, 7, 12, and 13), three had
aplastic disease (patients 2, 8, and 10), three had mild bone
disease (patients 4, 5, and 11), and one had mixed histology
(patient 9). The three patients with prior parathyroidectomy
(patients 1 to 3) had lower PTH levels than the other patients.
Five patients showed elevations of serum PTH after
deferoxamine, which ranged from 37 to 512 pg/mI above base-
line (mean change, 203 94 pg/mI). Two patients had declines
in serum PTH which were 31 and 86 pg/mI below baseline.
There was a positive correlation between serum PTH, both pre-
and post-treatment values, and osteoblastic osteoid (r =0.78, P
<0.001; N = 26).
Among the seven patients who had amino—terminal PTH
levels determined during a hypocalcemic challenge, before and
after deferoxamine treatment, six had aplastic bone disease and
Before DFO
Osteomalacia
Aplastic
Mild
Mixed
Osteitis
fibrosa
After DFO Clinically none of the patients in the asymptomatic group
developed bone symptoms or fractures during treatment with
Osteomalacia deferoxamine. Among the symptomatic patients (N=21), 17
showed moderate to marked improvement inbone pain and four
A I demonstrated no change in their bone symptoms. None hadP astic
worsening ofmusculoskeletal symptoms or developed fractures
during therapy.
Mild Among the seven patients with a prior parathyroidectomy,
stainable bone—surface aluminum decreasedafter deferoxamine
treatment (64 7 vs. 46 9%; P < 0.05), but no significant
Mixed changes were observed in osteoblastic osteoid (0.6 0.2 vs. 1.2
_________
0.4%) or BFR (25 14 vs. 69 20 m2/mm2/day). This
Osteitis contrasts to the changes seen in the group with intact parathy-
fibrosa roid glands as shown in Figure 3. There were no differences in
the total dose of deferoxamine administered or duration of
treatment between the two groups.
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Fig. 3. Stainable bone—surface aluminu,n, osteoblastic osteoid and
bone formation rate before and after treatment with deferoxamine in
patients with a prior parathyroidectomy (•—I; N = 7) and patients
with intact parathyroid glands (O--O; N = 20). (±) indicates P < 0.05
vs. before; (*) indicates P <0.01 vs. the group with parathyroidectomy.
one had osteomalacia; one patient also had a prior parathy-
roidectomy. Before deferoxamine, the maximum PTH increase
from baseline was 26 9 pg/mi and after treatment the
maximum PTH increase was 28 10 pg/mI. In this group there
was a significant decrease in stainable bone—surface aluminum
(56 5 vs. 10 3%, P < 0.02) and an increase in BFR (63 17
vs. 140 19 m2/mm2/day; P < 0.02), but no significant change
in osteoblastic osteoid (0.9 0.2 vs. 2.6 0.6; P = 0.063).
Discussion
We have shown that long—term deferoxamine therapy is
effective in removing aluminum from mineralized bone in
uremic patients with elevated bone aluminum. This response
was associated with improvement in bone mineralization as
shown by increases in bone apposition and bone formation rate,
which paralleled the increase in osteoblast number. As a result,
there was a favorable change in the histologic classification of
bone disease in the majority of patients.
The most common type of bone histology observed after
deferoxamine treatment in the patients who had a change in
bone histology was the mild lesion. The patients with either
mild (4 patients) or mixed bone disease (1 patient) before
treatment remained with that diagnosis on the followup bone
biopsy. Thus, only the patients with low turnover osteodystro-
phy (osteomalacia and aplastic disease) had a change in bone
histologic classification after deferoxamine.
Improvements in bone formation and bone histology after
deferoxamine treatment occurred despite the absence of an
increase in PTH (Table 4). However, there was a highly
significant positive correlation between the serum PTH and
osteoblastic osteoid (r = 0.78, P <0.001, N = 26) among the 13
patients who had PTH determinations, suggesting that small
increases in serum PTH may have been partially responsible for
some of the increases in osteoblast number. Interestingly, in the
seven patients in which amino—terminal PTH levels were mea-
sured after an acute hypocalcemic challenge, no increase in the
PTH response was seen after treatment. However, stainable
bone—surface aluminum decreased and bone formation in-
creased significantly in this group, suggesting that site—specific
aluminum removal caused an enhancement of bone formation
independent of any change in PTH in these patients.
The favorable changes we observed in bone apposition,
stainable bone—surface aluminum and osteoblastic osteoid after
long—term deferoxamine treatment are in agreement with the
bone histologic response of the three patients reported by
Malluche et al [13]. While the mean bone apposition rate
increased by more than 80% after treatment, there was a larger
percent increase in the mean double—tetracycline label length
(250%) which we attribute to the marked increase in the number
of active osteoblasts. In contrast to the findings of Malluche et
al [13], we found that the bone aluminum content decreased
only minimally in the 13 patients in which it was measured,
compared to the decline in stainable bone—surface aluminum.
Bone aluminum content decreased by only 18% while bone
surface aluminum decreased approximately 60% and bone
formation increased by more than 300% (Table 4). Moreover, in
this group of patients, the pretreatment bone aluminum—content
did not correlate with bone formation rate (r = 0.13), while
there was a significant negative correlation between stainable
bone—surface aluminum and bone formation rate (r = —0.69, P
<0.01). Thus, the small amounts of aluminum removed from
bone in our patients appeared to have little if any role in the
improved bone formation. Rather, the translocation of alumi-
num from the bone surface to the mineralized bone compart-
ment, as exemplified by the increase in stainable cement—line
aluminum, and the increase in osteoblast number, were the
major determinants of the increased bone—formation rate. From
this we conclude that the amount of aluminum on the bone
surface is a more sensitive indicator of the bone response to
aluminum chelation, and is, therefore, a better guide to chela-
tion therapy than is the change in bone aluminum content.
The optimum duration of therapy and the amount of
deferoxamine needed for successful treatment of aluminum—as-
60—
40
20—
Before After
6
4,
C0.— 'E'
.0 m—C Q 0(oc.-
Q ,.
.0
.n
.0
o
w.
coSon
2
Before After
Treatment of aluminum bone disease 1349
sociated bone disease cannot be determined from this study. It
appears, however, that a rather prolonged treatment schedule
may be necessary in the majority of patients. It is possible that
the concomitant administration of aluminum—containing phos-
phate binders in our patients may have contributed to this long
treatment period. Perhaps the use of calcium carbonate as a
phosphate binder[23] would adequately control serum phospho-
rus levels and allow for the discontinuation of aluminum binders
during chelation therapy. Whether the use of newer methods to
enhance aluminum removal during dialysis [24] can also make
chronic deferoxamine treatment more efficient remains to be
determined.
Patients who have had a parathyroidectomy prior to
deferoxamine therapy may require more intensive treatment
than patients with intact parathyroid glands. Among the six
patients with low turnover bone disease (3 with osteomalacia
and 3 with aplastic disease) who failed to change their bone
histologic classification (Fig. 2), five had undergone a para-
thyroidectomy prior to receiving deferoxamine. When all seven
patients with parathyroidectomy were analyzed together, a
very modest decrease in bone surface aluminum was noted in
the group, although osteoblastic osteoid and bone formation did
not improve (Fig. 3). The reason for their poor response to
treatment is unclear but may be related to a requirement for an
optimum level of circulating PTH for the maintenance of normal
bone formation. Thus, a greater dosage of deferoxamine may be
required in patients with prior parathyroidectomy. This dosage
adjustment should probably also include the discontinuation of
aluminum-containing phosphate binders. These data and the
finding that bone aluminum accumulation is enhanced after
parathyroidectomy [25—271 emphasize the need to develop
better treatments for secondary hyperparathyroidism.
In summary, we have shown that long—term aluminum chela-
tion therapy with deferoxamine effectively ameliorates alumi-
num associated, low—turnover renal osteodystrophy in patients
with intact parathyroid glands. Removal of aluminum from the
bone surface is associated with marked increases in osteoblast
number and bone formation, resulting in improved bone histol-
ogy. While small increases in serum PTH following aluminum
chelation may have an anabolic effect on bone function, alumi-
num removal alone can result in increased bone formation
without changes in PTH.
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